Literature DB >> 3872962

Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique.

D U Preiss, H Schmidt-Bleibtreu, P Berguson, G Metz.   

Abstract

Control of anticoagulation during cardiopulmonary bypass (CPB) with the automated activated whole blood clotting time (ACT) and reversal of heparin after CPB using a computerized ACT dose-response curve method resulted in significant reductions of blood transfusion requirements, surgical time, and protamine doses in 150 patients undergoing coronary artery bypass grafting procedures (ACT group) as compared to 200 patients for whom a standard fixed dose protocol for heparin and protamine was used (control patients). Mean transfusion requirements were 1,938 +/- 60 SEM ml whole blood and 853 +/- 48.3 SEM ml red blood cells for control patients and 1,397 +/- 59 SEM ml whole blood (P less than 0.001) and 695 +/- 34 SEM ml red blood cells (P less than 0.01) in the ACT group. ACT group patients also required less protamine with 26.2 +/- 0.60 SEM ml Protamine 1,000 (Roche) as compared to 33.9 +/- 0.49 SEM ml for control patients (P less than 0.001) but more heparin with 31,440 +/- 783 SEM I.U. versus 26,760 +/- 263 SEM I.U. (P less than 0.001). Surgical time decreased from 321 +/- 5.5 SEM min for control patients to 289 +/- 5.4 SEM min for ACT group patients (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872962     DOI: 10.1007/bf01731470

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Successful use of a reduced dose of protamine after cardiopulmonary bypass.

Authors:  A V Guffin; R W Dunbar; J A Kaplan; J W Bland
Journal:  Anesth Analg       Date:  1976 Jan-Feb       Impact factor: 5.108

2.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer.

Authors:  J A Young; C T Kisker; D B Doty
Journal:  Ann Thorac Surg       Date:  1978-09       Impact factor: 4.330

3.  Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis.

Authors:  J J Verska
Journal:  Ann Thorac Surg       Date:  1977-08       Impact factor: 4.330

4.  Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.

Authors:  R Babka; C Colby; A El-Etr; R Pifarré
Journal:  J Thorac Cardiovasc Surg       Date:  1977-05       Impact factor: 5.209

5.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.

Authors:  B S Bull; W M Huse; F S Brauer; R A Korpman
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

6.  Use of activated coagulation time to monitor heparin during cardiac surgery.

Authors:  J A Roth; R A Cukingnan; C R Scott
Journal:  Ann Thorac Surg       Date:  1979-07       Impact factor: 4.330

7.  Monitoring heparin anticoagulation and its neutralization.

Authors:  D R Jobes; A J Schwartz; N Ellison; R Andrews; R A Ruffini; J J Ruffini
Journal:  Ann Thorac Surg       Date:  1981-02       Impact factor: 4.330

8.  Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.

Authors:  R A Esposito; A T Culliford; S B Colvin; S J Thomas; H Lackner; F C Spencer
Journal:  J Thorac Cardiovasc Surg       Date:  1983-03       Impact factor: 5.209

9.  Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences.

Authors:  L R Whitfield; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

10.  Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.

Authors:  B F Akl; G M Vargas; J Neal; J Robillard; P Kelly
Journal:  J Thorac Cardiovasc Surg       Date:  1980-01       Impact factor: 5.209

View more
  1 in total

1.  Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.

Authors:  Ian J Welsby; Elizabeth McDonnell; Habib El-Moalem; Mark Stafford-Smith; John G Toffaletti
Journal:  J Clin Monit Comput       Date:  2002-07       Impact factor: 2.502

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.